DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study

Summary

The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks. Migraine patients will take DP-VPA or placebo (an inactive look-alike drug) every morning and will have to report any migraine attacks they have during the study's 18-week follow up.

Timeline

Start

2008-07

Primary completion

2009-06

Completion

2009-08

Outcome

Outcome not reported

Stopped: “STUDY WAS NOT STARTED”

Drugs

Indications